Concerns regarding increased prevalence of daptomycin (DAP)-resistant strains necessitate
novel therapies for Enterococcus faecium infections. Obligately lytic bacteriophages are …

Enterococcus faecium, a commensal of the human intestine, has emerged as a hospital-
adapted, multidrug-resistant (MDR) pathogen. Bacteriophages (phages), natural predators …

Background The combination of daptomycin (DAP) plus ampicillin (AMP), ertapenem (ERT),
or ceftaroline has been demonstrated to be efficacious against a DAP-tolerant Enterococcus …

Multidrug-resistant (MDR) Enterococcus faecium is a challenging pathogen known to cause
biofilm-mediated infections with limited effective therapeutic options. Lytic bacteriophages …

Enterococcus faecium is a difficult-to-treat pathogen with emerging resistance to most
clinically available antibiotics. Daptomycin (DAP) is the standard of care, but even high DAP …

Multidrug-resistant (MDR) Enterococcus faecium is a challenging nosocomial pathogen
known to colonize medical device surfaces and form biofilms. Bacterio (phages) may …

Enterococcus faecium is a member of the human gastrointestinal (GI) microbiota but can
also cause invasive infections, especially in immunocompromised hosts. Enterococci …

Abstract Objectives Enterococcus faecalis (Efc) and Enterococcus faecium (Efm) are
frequently resistant to vancomycin and β-lactams (BLs). In vitro data suggest synergy …

The deteriorating effectiveness of antibiotics is propelling researchers worldwide towards
alternative techniques such as phage therapy: curing infectious diseases using viruses of …

Vancomycin-resistant Enterococcus faecalis (VRE) has become a significant threat in
nosocomial settings. Bacteriophage (phage) therapy is frequently proposed as a potential …